DE69837539D1 - Löslicher laminin rezeptor vorläufer und verfahren zur verhinderung von laminins interaktionen - Google Patents

Löslicher laminin rezeptor vorläufer und verfahren zur verhinderung von laminins interaktionen

Info

Publication number
DE69837539D1
DE69837539D1 DE69837539T DE69837539T DE69837539D1 DE 69837539 D1 DE69837539 D1 DE 69837539D1 DE 69837539 T DE69837539 T DE 69837539T DE 69837539 T DE69837539 T DE 69837539T DE 69837539 D1 DE69837539 D1 DE 69837539D1
Authority
DE
Germany
Prior art keywords
tse
laminin receptor
laminin
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837539T
Other languages
English (en)
Other versions
DE69837539T2 (de
Inventor
Ernst-Ludwig Winnacker
Stefan Weiss
Frank Edenhofer
Roman Rieger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNIVERSITY OF THE WITWATERSRAND JOHANNESBURG, , ZA
Original Assignee
Stefan Weiss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stefan Weiss filed Critical Stefan Weiss
Application granted granted Critical
Publication of DE69837539D1 publication Critical patent/DE69837539D1/de
Publication of DE69837539T2 publication Critical patent/DE69837539T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69837539T 1997-05-30 1998-05-29 Löslicher Lamininrezeptor Vorläufer und Verfahren zur Verhinderung von Laminininteraktionen Expired - Lifetime DE69837539T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97108712 1997-05-30
EP97108712 1997-05-30
PCT/EP1998/003220 WO1998053838A2 (en) 1997-05-30 1998-05-29 A soluble laminin receptor precursor and methods to inhibit its interactions

Publications (2)

Publication Number Publication Date
DE69837539D1 true DE69837539D1 (de) 2007-05-24
DE69837539T2 DE69837539T2 (de) 2008-01-03

Family

ID=8226854

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837539T Expired - Lifetime DE69837539T2 (de) 1997-05-30 1998-05-29 Löslicher Lamininrezeptor Vorläufer und Verfahren zur Verhinderung von Laminininteraktionen

Country Status (7)

Country Link
EP (2) EP1127894A1 (de)
JP (1) JP2002501385A (de)
AT (1) ATE359298T1 (de)
AU (1) AU7917598A (de)
CA (1) CA2291720A1 (de)
DE (1) DE69837539T2 (de)
WO (1) WO1998053838A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
DE19918141A1 (de) 1999-04-21 2000-10-26 Boehringer Ingelheim Vetmed Verfahren zur Diagnose von übertragbaren Spongiformen Enzephalopathien
DE19925073C2 (de) * 1999-06-01 2001-07-19 Stefan Weiss Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung
DE10106076A1 (de) * 2001-02-08 2002-08-22 Susanne Wylezalek Verwendung von Lathyrus Sativus L. zur Herstellung eines Medikamentes zur Behandlung von BSE und BSE-ähnlichen Krankheiten
US20030118585A1 (en) 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
DE10346627A1 (de) * 2003-10-08 2005-05-19 Weiss, Stefan, PD Dr. Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung
GB201519557D0 (en) * 2015-11-05 2015-12-23 Univ Witwatersrand Jhb Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
GB201700529D0 (en) * 2017-01-12 2017-03-01 Rogers April Laminin receptor peptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180809A (en) * 1988-05-20 1993-01-19 La Jolla Cancer Research Foundation Adhesion receptor for laminin and its use
AU3766989A (en) * 1988-05-20 1989-12-12 La Jolla Cancer Research Foundation Adhesion receptor for laminin and its use
DK0616613T3 (da) * 1991-12-03 1999-09-27 Proteus Molecular Design Fragmenter af prionprotein
CA2256312A1 (en) * 1996-05-29 1997-12-04 Mcgill University Prion protein binding proteins and uses thereof
DE69739210D1 (de) * 1997-12-16 2009-02-26 Univ Zuerich Diagnostik für übertragbare spongiforme Enzephalopathie

Also Published As

Publication number Publication date
EP1127894A1 (de) 2001-08-29
EP0984987A2 (de) 2000-03-15
JP2002501385A (ja) 2002-01-15
DE69837539T2 (de) 2008-01-03
WO1998053838A3 (en) 1999-05-14
CA2291720A1 (en) 1998-12-03
EP0984987B1 (de) 2007-04-11
ATE359298T1 (de) 2007-05-15
WO1998053838A2 (en) 1998-12-03
AU7917598A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
DE60128249D1 (de) Verfahren zur diagnose von immunologischer lebensmittelsensitivität
JP2019535015A5 (de)
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
Schuppan Connective tissue polypeptides in serum as parameters to monitor antifibrotic treatment in hepatic fibrogenesis
CA2566040A1 (en) Method for increasing the dynamic measuring range of test elements, especially immunological test elements, that are based on specific binding reactions
DE69837539D1 (de) Löslicher laminin rezeptor vorläufer und verfahren zur verhinderung von laminins interaktionen
ATE460430T1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
CA2264939A1 (en) Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes
DE60025347D1 (de) Methoden zur vohersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
GB2029011A (en) The use of a synthetic bifunctional ligand for the immunometric determination of the concentration ratio of two solutes
BR0009843A (pt) Método de diagnosticar encefalopatias esponjiformes transmissìveis
WO2006004958A3 (en) Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
WO2009066787A1 (ja) 血液試料の品質評価方法
ATE382861T1 (de) Universeller biosensor und verfahren zur verwendung
DK1090297T3 (da) Fremgangsmåde til påvisning af et antistof i en væskepröve
HUP0100948A2 (hu) Antitest kompeticiós teszt (AKT) P-glikoprotein és egyéb sejtfelszíni receptorok, pumpák és fehérjék konformáció-változásainak kvalitatív, illetve konformáció-függő kvantitatív kimutatására és annak alkalmazásai
JPH08304406A (ja) カリブレーターマトリックス
WO2003101176A8 (en) Method, composition and kit for antigenic binding of norwalk-like viruses
WO1999047932A3 (en) Diagnosis of spongiform or de-myelinating disease
ATE203999T1 (de) Monoklonaler antikörper und seine verwendung in einem immunoassay
CA2409208A1 (en) Method for examining wt1-related disease
DE60038557D1 (en) Assay
SE9602234D0 (sv) A novel diagnostic method utilizing ECP, and reagents to be used in the methods
DE69836279D1 (de) Neue verbindung, 2-amino-3-ä2-(aplpha-mannopyranosyl) indol-3-ylü propionsäure, verfahren zur herstellung und methoden zur in vivo untersuchung mit der neuen verbindung
Benattar et al. A new dilution for the modified APTT-based assay for activated protein C resistance: improvement of the reliability in patients with a lupus anticoagulant

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UNIVERSITY OF THE WITWATERSRAND JOHANNESBURG, , ZA